| Primary |
| Prothrombin Time Prolonged |
17.9% |
| Anaemia |
10.7% |
| Coagulopathy |
10.7% |
| Transfusion-related Acute Lung Injury |
10.7% |
| Anticoagulant Therapy |
7.1% |
| Blood Product Transfusion |
7.1% |
| Gastrointestinal Haemorrhage |
7.1% |
| Haemorrhage |
7.1% |
| Activated Partial Thromboplastin Time Prolonged |
3.6% |
| Haemoglobin Decreased |
3.6% |
| Procoagulant Therapy |
3.6% |
| Renal Failure |
3.6% |
| Thrombosis |
3.6% |
| Thrombotic Thrombocytopenic Purpura |
3.6% |
|
| Transfusion-related Acute Lung Injury |
42.4% |
| Pulmonary Oedema |
12.1% |
| Lung Infiltration |
6.1% |
| Wheezing |
6.1% |
| Acute Respiratory Failure |
3.0% |
| Blood Product Transfusion |
3.0% |
| Cardiac Failure |
3.0% |
| Feeling Abnormal |
3.0% |
| Pleural Effusion |
3.0% |
| Respiratory Disorder |
3.0% |
| Respiratory Distress |
3.0% |
| Transfusion Reaction |
3.0% |
| Transfusion Related Complication |
3.0% |
| Transfusion-related Circulatory Overload |
3.0% |
| Virus Serology Test Positive |
3.0% |
|
| Secondary |
| Shock Haemorrhagic |
16.9% |
| Haemorrhagic Disorder |
9.0% |
| Renal Transplant |
8.6% |
| Sedation |
6.8% |
| Drug Use For Unknown Indication |
4.5% |
| Immunosuppression |
4.5% |
| Infection |
4.5% |
| Acute Myeloid Leukaemia |
3.8% |
| Coagulopathy |
3.8% |
| Haemolytic Uraemic Syndrome |
3.8% |
| Hepatic Failure |
3.8% |
| Product Used For Unknown Indication |
3.8% |
| Blood Product Transfusion |
3.4% |
| Gastroenteritis |
3.4% |
| Influenza Like Illness |
3.4% |
| Lymph Node Pain |
3.4% |
| Lymphadenopathy |
3.4% |
| Procedural Haemorrhage |
3.4% |
| Cerebral Haemorrhage |
3.0% |
| Ischaemic Stroke |
3.0% |
|
| Hepatitis B |
13.0% |
| Ventricular Tachycardia |
11.1% |
| Hepatitis C |
9.3% |
| Transmission Of An Infectious Agent Via A Medicinal Product |
9.3% |
| Pulmonary Oedema |
7.4% |
| Transfusion-related Acute Lung Injury |
7.4% |
| Lymphadenopathy |
5.6% |
| Tongue Oedema |
5.6% |
| Haemorrhage |
3.7% |
| Hepatitis Post Transfusion |
3.7% |
| Loss Of Consciousness |
3.7% |
| Transfusion-related Circulatory Overload |
3.7% |
| Viral Myocarditis |
3.7% |
| Anaphylactic Shock |
1.9% |
| Bile Duct Stone |
1.9% |
| Blood Product Transfusion |
1.9% |
| Bronchospasm |
1.9% |
| Deep Vein Thrombosis |
1.9% |
| Disseminated Intravascular Coagulation |
1.9% |
| Hepatitis Fulminant |
1.9% |
|
| Concomitant |
| Product Used For Unknown Indication |
34.7% |
| Drug Use For Unknown Indication |
12.8% |
| Coronary Artery Bypass |
10.9% |
| Aortic Valve Replacement |
4.4% |
| Prophylaxis |
3.8% |
| Infection Prophylaxis |
3.5% |
| Catheterisation Cardiac |
3.5% |
| Coagulopathy |
3.3% |
| Mitral Valve Replacement |
3.2% |
| Haemorrhage |
2.8% |
| Acute Myeloid Leukaemia |
2.3% |
| Gastric Cancer |
2.2% |
| Hypertension |
1.8% |
| Thrombocytopenia |
1.7% |
| Disseminated Intravascular Coagulation |
1.6% |
| Ill-defined Disorder |
1.5% |
| Intra-aortic Balloon Placement |
1.5% |
| Nausea |
1.4% |
| Surgery |
1.4% |
| Tricuspid Valve Repair |
1.4% |
|
| Pain |
12.5% |
| Injury |
11.7% |
| Unevaluable Event |
8.5% |
| Anhedonia |
7.3% |
| Fear |
7.0% |
| Renal Failure |
7.0% |
| Anxiety |
5.2% |
| Sepsis |
5.2% |
| Multi-organ Failure |
4.6% |
| Renal Impairment |
4.4% |
| Emotional Distress |
3.7% |
| Stress |
3.6% |
| Renal Failure Acute |
3.3% |
| Upper Gastrointestinal Haemorrhage |
3.3% |
| Death |
3.0% |
| Renal Injury |
2.5% |
| Depression |
2.0% |
| Drug Ineffective |
1.9% |
| Septic Shock |
1.7% |
| White Blood Cell Count Decreased |
1.7% |
|
